Track topics on Twitter Track topics that are important to you
The study aims at determining the feasibility of using maintenance Decitabine therapy following remission induction and consolidation in elderly Acute Myeloid Leukemia patients who are fit for aggressive therapy.
Primary: Safety and tolerability of the decitabine regimen in the post remission state.
1. Disease-free survival - To determine the one-year disease-free survival in elderly patients with acute myeloid leukemia (AML) in complete remission treated with Decitabine as post-consolidation maintenance therapy.
2. Overall survival
The median age of patients with AML at presentation is between 65 to 70 years (Peterson 1977, Brincker 1985, Baudard 1994) and the incidence of AML increases with advancing age (Wingo 1995). Given this, increased attention should be focused on adult patients 60 years or older with this disease. Treatment strategies in younger patients are well established however therapy in the elderly deserves particular thought (Foon 1981, Sebban 1998, Lowenberg 1998). Also progress in the treatment of AML in the elderly population is not near progress that has been made in the treatment of the younger population (Stone 2002, Kantarjian 2006). Poor tolerability and questionable treatment benefit have left older adult patients with AML often without effective treatment options or with best supportive care. According to Medicare records, only 30% of a cohort of 2657 AML patients older than 65 years were provided chemotherapy treatment (44% in patients 65 to 74 years, 24% in patients 75 to 84, and 6% in patients 85 and above). The mortality was 86% at 1 year and 94% at 2 years following the diagnosis. The overall survival in this cohort was only 2 months (Menzin 2002). The study could not distinguish between intensive induction chemotherapy and palliative therapy.
Despite modest improvements in outcomes for younger patients with AML, adults over 55 years of age (the majority of patients with AML) continue to do poorly (Tallman 2005).
In patients over 60 years response rates have ranged from 40% to 55% and in patients over 70 years have ranged from 24% to 33% (Buchner 2009, Estey 2007, Lowenberg 1998, Rowe 2004). Patient and leukemia related factors could explain the poor result of older patients with AML (Harry 2007, Gupta 2005). Also in patients over 60, with adverse cytogenetics the response rates range from 26% to 34%; with antecedent hematologic disorder they range between 28% and 46%; and with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 it is around 26%. (Grimwade 2001, Rowe 2004, Appelbaum 2006).
For the past several decades, standard induction chemotherapy for acute myeloid leukemia (AML) has consisted of the "7+3" regimen of cytarabine plus an anthracycline. Standard consolidation chemotherapy has consisted of high dose cytarabine for 3-4 cycles. Few trials have randomized older patients with AML to receive standard remission induction (i.e., anthracycline-containing) chemotherapy versus either palliative therapy or less intensive chemotherapy. The median survival of older adults with AML treated with cytarabine plus an anthracycline on the "7+3" schedule is 8 to 12 months (Estey 2007, Rowe 2004). Less than 10% of patients remain in remission for more than 3 years. (Lowenberg 1998, Godwin 2003, Roboz 2007).
The European Organization for the Research and Treatment of Cancer (EORTC) conducted a trial on 60 patients and randomized them to intensive chemotherapy (daunorubicin 30 mg/m2/day intravenously [IV] for 3 days, vincristine 1 mg/m2/day IV on Day 2, cytarabine 100 mg/m2/day IV for 7 days with 50 mg/m2/day IV bolus every 12 hours for 7 days) or a "watch and wait" approach (supportive care alone with hydroxyurea 3 g PO on Days 1 and 4 and LDAC (subcutaneous cytarabine) 100 mg/m2 every 12 hours SC on Days 2, 3, 5, and 6 administered only when leukemia-related symptoms occurred). All patients were more than 65 years old, but had to have preserved organ function and performance status. The patients who received induction chemotherapy had a higher complete remission (CR) rate (58% vs. 0%), lower incidence of early mortality (3/31 vs. 18/29 patients), longer median survival (21 weeks vs. 11 weeks) and greater chance of survival at 2.5 years (17% vs. 0%). The median duration of hospitalization did not statistically differ between the two groups.
In the study performed by Tilly et al (Tilly 1990) in patients >65 years old, 87 patients were randomized to receive either LDAC 10 mg/m2 SC every 12 hours for 21 days or standard chemotherapy induction with rubidazone (a daunorubicin-derived agent) 100 mg/m2 IV for 4 days plus cytarabine 200 mg/m2 IV for 7 days. The combination chemotherapy arm was associated with a 31% early death rate compared with10% in the lower dose arm. There was a higher CR rate in the rubidazone/cytarabine arm (52% versus 32%), but only a trend toward improved survival favoring this arm (12.8 months versus 8.8 months) was reported.
Repetitive cycles of high dose Cytarabine (HiDAC- 3 g/m2 ARA-C twice a day on days 1, 3, 5) is an effective consolidation regimen for AML patients based on the CALGB in 1994 (Mayer 1994). In patients younger than 60, this protocol produced a high rate of continuous CR. However in patients older than 60, a high rate of neurotoxicity was reported using this regimen (Mayer 1994). A follow up study modified this protocol by using Intermediate Dose Cytarabine (IDAC) (1 g/m2 ARA-C twice a day on days 1, 3, 5) and applied the regimen to a group of elderly patients (≥60 years) with de novo AML. This protocol (IDAC) was found to be an effective and well-tolerated consolidation regimen for elderly patients (Sperr 2004). Based on this study the median overall survival, disease-free survival, and continuous CR were 10.6, 15.5, and 15.9 months, respectively (Sperr 2004).
Thus, from the data obtained in these studies, chemotherapy in some form is superior to best supportive care alone or best supportive care with chemotherapy initiated after evidence of disease progression. However no single treatment approach appears adequate and can be considered the standard of care for elderly AML patients. Thus, improved treatment strategies and more suitable chemotherapy regimens are needed (Harry 2007). Additionally, it is not clear how best to administer chemotherapy with currently available drugs, taking into account induction and consolidation treatments.
Several different categories of new therapies are under development, including multidrug resistance (MDR) reversal agents, immunomodulatory therapies, and signal transduction targeting. Table 1 shows examples of targets and agents developed and being developed. Given the lack of standards in the treatment of elderly AML, of the use of these newer agents in treating AML is justified.
Table 1: Targets for New Agents for Acute Myelogenous Leukemia (Medscape.com) Targets Agents CD33 Gemtuzumab ozogamicin CD45 131I-anti-CD45 MDR1/Pgp Cyclosporine, PSC-833 Angiogenesis and/or VEGF Thalidomide, SU-5416, bevacizumab antibodies Hypermethylated chromatin Decitabine Histone deacetylase Phenylbutyrate trichostatin A, trapoxin Bcl-2 Bcl-2 antisense S-phase checkpoint UCN-01 20S proteasome PS-341 Tyrosine kinase (c-kit receptor) STI-571 Flt-3 kinase CEP-701 Farnesyl transferase BMS-214662, R115777
A sizeable percentage of older adults attain a complete remission with induction chemotherapy, but almost all of these patients will relapse within a median of four to eight months unless given additional cytotoxic therapy (Cassileth 1999). Even with post-remission therapy, relapses are common. Furthermore, post-remission therapy in older adults is complicated by high rates of treatment related toxicity.
To address the problem of post-remission therapy, the Nordic MDS group performed a phase II multicenter study, which studied long-term maintenance with azacitidine. They studied patients with high-risk MDS and AML arising from MDS. The mean age of the group was 68 years. Patients who achieved CR after induction received low dose azacitidine sq 5 out of 28 days until relapse. They noted a median CR duration of 13.5 months and noted very mild side effects (Grovdal 2008).
In another phase II trial Decitabine was used for untreated AML patients older than 60 who were not candidates for intensive chemotherapy (or who refused it). PS was ECOG <3. All pts received induction with Decitabine at 20mg/m2 IV on days 1-10 of a 4 week cycles. Patients with persistent AML at the end of a cycle received a repeat of the 10 day course, but responding patients received maintenance with shortened courses of 3-5 days depending on the degree and duration of neutropenia. Forty two percent of patients achieved CR. Median OS has not yet been reached; median f/u of 19 surviving patients was 8 months. The median number of cycles received till the date of publication was five (Blum 2009).
One retrospective study studied 141 elderly AML patients in first CR after 7+3 induction chemotherapy. In patients aged 60-70 year, consolidation ± maintenance therapy improved outcomes (DFS and OS). In patients older than 70 and with WBC < 30 x109/l maintenance therapy without consolidation improved outcomes. In patients older than 70 and with WBC < 30 x 109/l consolidation therapy worsened outcomes. In patients older than 70 and with WBC > 30 x 109/l, both consolidation and/or maintenance therapy did not improve outcomes (Corre 2005).
The purpose of this study is to determine whether it is feasible to use maintenance treatment (prolonged treatment over several months) with Decitabine in elderly patients with AML after they have obtained a remission with standard chemotherapy. The study also aims at obtaining preliminary results on whether this approach prolongs the period of remission after standard chemotherapy. The study group will include elderly (≥60 years of age), Acute Myeloid Leukemia (AML) patients who can tolerate an aggressive therapy.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Acute Myeloid Leukemia
University of Utah, Huntsman Cancer Institute
Salt Lake City
Not yet recruiting
University of Utah
Published on BioPortfolio: 2014-08-27T03:12:43-0400
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus JNJ-56022473 (Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
The primary objective of study Part A is to assess the safety of JNJ-56022473 (formerly CSL362) monotherapy and confirm the recommended Phase 2 dose (RP2D) in participants with acute myel...
The purpose of this study is to compare the results in older patients who have newly diagnosed or secondary acute myeloid leukemia (AML) and who are to either receive decitabine or patient...
The purpose of this study is to examine the safety and efficacy of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukemia (A...
This pilot clinical trial studies potential genetic markers which might be used to predict which patients with acute myeloid leukemia or myelodysplastic syndromes respond to decitabine. Th...
In this study, the investigators seek to determine whether decitabine therapy can improve outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML) patie...
Background The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. Methods We enrolled 84 a...
The refractory nature of many cancers remains the main health challenge over the past century. The epigenetic drug, decitabine (DAC), represents one of the most promising therapeutic agents in cancers...
The simultaneous Occurrence of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) has been rarely reported. Most of these cases have been occurring more frequently as a secondary even...
Patients with Down syndrome (DS) are predisposed to acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in early and later childhood, respectively, but rarely experience both. We herei...
A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.
A rare acute myeloid leukemia characterized by abnormal EOSINOPHILS in the bone marrow.
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Palliative care is the active holistic care of patients with advanced progressive illness. Management of pain and other symptoms and provision of psychological, social and spiritual support is paramount. The goal of palliative care is achievement of the ...
decitabine `10 days with cytarabine for amlchemoregimen.com decitabinedacogen for aml remissiondacogen iv for 10 days in aml5 day vs 10 day decitabinedacogen for elderlydecitabine aml protocoldacogen for acute monocytic leukemiadecitabine 10 daysdecitabine aml protocoldacogen for aml for 10 daysdecitabine for AML for 10 dayshow many days is decitabine cycle aml10 day dacogen and AML56022473 AML2002 TRIAL